ZEALAND PHARMA AS

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for survodutide, a dual glucagon/GLP-1 receptor agonist, for treating non-cirrhotic MASH with moderate or advanced fibrosis. The company also initiates two Phase III studies, LIVERAGE and LIVERAGE-Cirrhosis, to assess survodutide's efficacy in MASH patients with fibrosis and cirrhosis.

Zealand Pharma announces Boehringer's U.S. FDA Breakthrough Therapy designation for survodutide in MASH and fibrosis, and the initiation of two Phase III trials, LIVERAGE and LIVERAGE-Cirrhosis.

Zealand Pharma reports Boehringer Ingelheim's U.S. FDA Breakthrough Therapy designation for survodutide in treating non-cirrhotic MASH and moderate or advanced fibrosis, and the initiation of two Phase III trials, LIVERAGE and LIVERAGE-Cirrhosis, for MASH and fibrosis.

Zealand Pharma A/S announces total shares and voting rights as of September 30, 2024, with 71,023,871 shares and voting rights each.

FDA to decide on Biofrontera's Ameluz dose increase, BMS's perioperative Opdivo regimen for NSCLC, and Zealand Pharma's dasiglucagon for CHI by early October.

DSV A/S initiated a share buyback program on 24 April 2024, aiming to purchase up to DKK 1,000 million worth of shares by 23 July 2024, in compliance with MAR and Safe Harbour rules. As of 7 June 2024, 497,100 shares were bought back at an average price of 1,050.59 DKK, totaling DKK 509,446,980.

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.